Odyssey Therapeutics, Inc. (ODTX) competitors & alternatives
Health Care · NASDAQ
Odyssey Therapeutics, Inc. (ODTX)'s top competitors and alternatives — its most similar public companies — include GENERATE BIOMEDICINES INC (GENB), ATAIBECKLEY INC (ATAI), TYRA BIOSCIENCES INC (TYRA), Aldeyra Therapeutics, Inc. (ALDX), ANNEXON INC (ANNX), CULLINAN THERAPEUTICS INC (CGEM), REZOLUTE INC (RZLT), ELEDON PHARMACEUTICALS INC (ELDN), DESIGN THERAPEUTICS INC (DSGN), TREVI THERAPEUTICS INC (TRVI), CLIMB BIO INC (CLYM) and MBX BIOSCIENCES INC (MBX). These are Odyssey Therapeutics, Inc.'s closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top ODTX competitors & alternatives
-
GENERATE BIOMEDICINES INCGENBHealth Care
Generate Biomedicines is a clinical-stage biotechnology company leveraging generative artificial intelligence to design novel, programmable protein…
$13.90 (as of 2026-07-22) · market cap $1.8B
-
ATAIBECKLEY INCATAIHealth Care
A clinical-stage biotechnology company dedicated to developing innovative mental health therapies through a diverse pipeline of neuropsychiatric treatments.
$7.18 (as of 2026-07-22) · market cap $2.7B
-
TYRA BIOSCIENCES INCTYRAHealth Care
Tyra Biosciences is a clinical-stage biotech company developing precision small-molecule inhibitors to overcome drug resistance in cancer, particularly…
$30.59 (as of 2026-07-22) · market cap $1.8B
-
Aldeyra Therapeutics, Inc.ALDXHealth Care
Aldeyra is a clinical-stage biotech pursuing FDA approval of reproxalap, an aldehyde dehydrogenase activator for ophthalmologic inflammation, dependent on…
$1.70 (as of 2026-07-22) · market cap $106M
-
ANNEXON INCANNXHealth Care
Annexon is a clinical-stage biotechnology company developing C1q-inhibitor therapies to treat neurodegenerative and autoimmune diseases driven by the classical…
$5.23 (as of 2026-07-22) · market cap $857M
-
CULLINAN THERAPEUTICS INCCGEMHealth Care
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing targeted, innovative therapies for cancer and autoimmune diseases.
$17.65 (as of 2026-07-22) · market cap $1.1B
-
REZOLUTE INCRZLTHealth Care
Rezolute is a clinical-stage biopharmaceutical company developing targeted therapeutic solutions for rare and chronic metabolic and endocrine diseases.
$5.00 (as of 2026-07-22) · market cap $481M
-
ELEDON PHARMACEUTICALS INCELDNHealth Care
Eledon Pharmaceuticals is a clinical-stage biotech developing immune-modulating therapies for autoimmune diseases and organ transplantation.
$3.72 (as of 2026-07-22) · market cap $287M
-
DESIGN THERAPEUTICS INCDSGNHealth Care
A clinical-stage biotechnology company pioneering a novel class of small-molecule GeneTAC therapeutics to treat serious genetic diseases by modulating gene…
$11.78 (as of 2026-07-22) · market cap $736M
-
TREVI THERAPEUTICS INCTRVIHealth Care
Trevi Therapeutics is a clinical-stage biotech developing Haduvio, an oral, non-scheduled dual-action opioid receptor drug, to treat chronic cough associated…
$17.36 (as of 2026-07-22) · market cap $2.5B
-
CLIMB BIO INCCLYMHealth Care
Clinical-stage biotech developing budoprutug, an anti-CD19 monoclonal antibody for B-cell depletion in autoimmune diseases including membranous nephropathy and…
$12.58 (as of 2026-07-22) · market cap $720M
-
MBX BIOSCIENCES INCMBXHealth Care
A clinical-stage biopharmaceutical company leveraging a proprietary platform to optimize drug candidate properties and develop therapies across multiple…
$58.30 (as of 2026-07-22) · market cap $2.9B
Not quite? Describe exactly what you want →
Peers are Odyssey Therapeutics, Inc.'s closest public companies by shared sub-industry, sector and business themes. See the full profile: Odyssey Therapeutics, Inc. (ODTX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.